Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases A Case Matched Control Study
Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor
(VEGF) increasingly added to other drugs in the treatment of colorectal cancer. Bev is
typically used in combination with other chemotherapeutic agents such as oxaliplatin,
irinotecan, leucovorin and 5-fluorouracil (5-FU) for treatment of patients with CRLM. The
objective of this study was to assess the impact of neoadjuvant bevacizumab on clinical
outcome after hepatectomy of colorectal liver metastases (CRLM).
Patients, who underwent liver resection due to colorectal liver metastases after neoadjuvant
chemotherapy, operated between 2005 and 2007 will be evaluated retrospectively. The patients
will be distributed in two groups, either with or without bevacicumab. Outcome parameters
are mortality, complications, hospital stay and ICU stay. To increase the power of the study
the total number of patients will be increased by adding patients from other centers.
Results will be adjusted for the propensity of developing complications.
Observational Model: Cohort, Time Perspective: Retrospective
Stefan Breitenstein, MD
Departement of Visceral and Transplantation Surgery of University hospital of Zurich
Switzerland: Ethic committee of Kanton Zurich,